Discover Latest #Expectation News, Articles and Videos with Contenting

Eurozone Gross Domestic Product s.a. (YoY) above expectations (1.2%) in 1Q: Actual (1.5%)

Eurozone Gross Domestic Product s.a. (YoY) above expectations (1.2%) in 1Q: Actual (1.5%)

Eurozone Employment Change (QoQ) came in at 0.2%, below expectations (0.3%) in 1Q

Eurozone Employment Change (QoQ) came in at 0.2%, below expectations (0.3%) in 1Q

Eurozone retail sales inch up 0.1% mom April, mixed national trends - Action Forex

Eurozone retail sales rose just 0.1% mom in April, falling short of expectations for a 0.2% mom rise. Modest gains in food, drink, and tobacco sales (+0.5%) and a solid rebound in automotive fuel purchases (+1.3%) were offset by a -0.3% decline in non-food product sales.

Thailand Consumer Prices Fall for 2nd Month - ForexTV

In May 2025, Thailand experienced a year-on-year decrease in consumer prices by 0.57%, marking the second consecutive month of deflation. This decline follows a 0.22% reduction in April and was slightly less than the anticipated market forecast of a 0.83% decrease. The deflationary trend was observed across most sub-indexes, including housing and furnishings, which fell to -0.30% from -0.67% in April; medical and personal care, which dropped to -1.05% from -0.72%; transport, which decreased further to -3.38% from -2.97%; clothing and footwear, which declined to -0.91% from -0.56%; and other non-food and beverage categories, which fell to -1.51% from -1.45%. Conversely, the inflation rate for food and non-alcoholic beverages decreased to 0.89%, marking its lowest point in 11 months and down from 1.63% in April. On a monthly basis, the Consumer Price Index (CPI) experienced a rise of 0.26%, bouncing back from a 0.21% decline in the preceding period. Furthermore, annual core inflation increased to 1.09% from the previous 0.98%, failing to meet the market's expectation of a slight decrease to 0.95%. This represents the highest core inflation rate since June 2023.The material has been provided by InstaForex Company - www.instaforex.com

Huize Holding Limited Reports First Quarter 2025 Unaudited Financial Results - ForexTV

SHENZHEN, China, June 06, 2025 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data-driven and AI-powered solutions in Asia, today announced its unaudited financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial and Operational Highlights Robust growth in insurance premiums: Gross written premiums (“GWP”) reached RMB1,437.3 million for the first quarter of 2025, representing an increase of 37.8% from RMB1,043.0 million in the final quarter of 2024. First year premiums (“FYP”) also rose 30.9% sequentially to RMB730.4 million in the first quarter of 2025. Increases in premiums were driven primarily by our high-quality customer base, sustainably high persistency ratios, and the diverse insurance product offerings that we provide on our platform.Improving operational efficiency: Total operating expenses declined by 28.9% sequentially to RMB82.7 million in the first quarter of 2025. Our expense-to-income ratio improved significantly from 40.7% in the final quarter of 2024 to 29.1% in the first quarter of 2025, reflecting the operational efficiency improvement driven by our recent cost-optimization initiatives and the integration of our proprietary AI into everyday workstreams.The cumulative number of insurance clients served increased to 11.0 million as of March 31, 2025. Huize cooperated with 143 insurer partners in mainland China and internationally, including 83 life and health insurance companies and 60 property and casualty insurance companies, as of March 31, 2025.As of March 31, 2025, cash and cash equivalents were RMB201.7 million (US$27.8 million). Mr. Cunjun Ma, Founder and CEO of Huize, said, “We are pleased to deliver another quarter of resilient business results, with operating revenue exceeded RMB280 million, while gross written premiums and first-year premiums facilitated on our platform increasing 38% and 31% sequentially, reaching RMB1.4 billion and RMB730 million, respectively.” “Throughout the quarter, we remained focused on acquiring and serving high-quality, mass-affluent customers. The average age of customers who purchased long-term insurance products in the quarter was 35.0 years old, among which 66.4% were in higher-tier cities. By the end of February, our 13th and 25th month persistency ratios for long-term life and health insurance products remained at industry-high levels of more than 95%, reflecting the high quality of customers we acquired through various channels.” “We continue to develop and launch differentiated customized products with insurer partners. Market demand for wealth protection solutions has intensified amid a declining interest rate environment. In response, we partnered with New China Life to launch “Bliss No. 3,” a savings product striving to achieve sustainable returns for customers. Additionally, we expanded our portfolio of customized participating products. Building on the “Fu Man Jia” series co-launched with Aviva-COFCO, we partnered with Cathay Lujiazui Life Insurance on “Jin Man Yi Zu No.6”, a participating incremental whole life insurance product. This was followed by the launch of “Xing Hai Hui Xuan”, a participating annuity product co-developed with Pramerica Fosun Life Insurance. These customized products were designed to cater to the industry-wide demand shift from fixed returns to floating-returns, further solidifying our leadership in China’s participating insurance segment.” “Our proprietary AI solutions are increasingly integrated across our operations, enhancing service efficiency and supporting sustainable growth. Notably, our expense-to-income ratio fell by 11.5 percentage points sequentially, reaching 29.1% in the first quarter of 2025. With private large-language model deployments, we are not only realizing meaningful cost savings, but also reinforcing the security and effectiveness of our data capabilities, ensuring regulatory compliance.” “During the quarter, we launched an AI-powered smart portal on Huize’s app, offering 24/7 insurance agent support. Our AI services now cover key customer lifecycle touchpoints including policy inquiries and product matching, serving an average of over 15,000 users daily. We are also revolutionizing after-sales claims processing through Xiao Ma Claim’s AI agents, achieving end-to-end automation of claims reporting, review, and payout. This innovation is expected to reduce processing time on Xiao Ma Flash Claim from one day to one hour upon full rollout. In the first quarter, Xiao Ma Claim facilitated RMB190 million in claims across 36,000 cases, providing customers with efficient and reliable insurance claim services.” First Quarter 2025 Financial Results GWP and operating revenue GWP facilitated on our platform was RMB1,437.3 million (US$198.1 million) in the first quarter of 2025, a decrease of 16.3% from RMB1,718.0 million in the same period of 2024. Within GWP facilitated in the first quarter of 2025, FYP accounted for RMB730.4 million (or 50.8% of total GWP), a decrease of 14.8% year-over-year. Renewal premiums accounted for RMB706.8 million (or 49.2% of total GWP), a decrease of 17.9% year-over-year. Operating revenue was RMB283.8 million (US$39.1 million) in the first quarter of 2025, a decrease of 8.5% from RMB310.3 million in the same period of 2024. The decrease was primarily driven by the decrease in FYP facilitated. Operating costs Operating costs were RMB210.5 million (US$29.0 million) in the first quarter of 2025, a decrease of 4.4% from RMB220.2 million in the same period of 2024, primarily due to a decrease in channel expenses. Operating expenses Selling expenses were RMB47.3 million (US$6.5 million) in the first quarter of 2025, an increase of 7.0% from RMB44.2 million in the same period of 2024, primarily due to an increase in advertising and marketing expenses. General and administrative expenses were RMB21.9 million (US$3.0 million) in the first quarter of 2025, a decrease of 3.2% from RMB22.6 million in the same period of 2024. This decrease was primarily due to a decrease in rental and utilities expenses. Research and development expenses were RMB13.5 million (US$1.9 million) in the first quarter of 2025, a decrease of 6.3% from RMB14.4 million in the same period of 2024, primarily due to a decrease in rental and utilities expenses. Net loss and non-GAAP net loss for the period Net loss attributable to common shareholders was RMB8.6 million (US$1.2 million) in the first quarter of 2025, compared to net profit attributable to common shareholders of RMB6.9 million in the same period of 2024. Non-GAAP net loss attributable to common shareholders1 was RMB10.9 million (US$1.5 million) in the first quarter of 2025, compared to non-GAAP net profit attributable to common shareholders of RMB4.4 million in the same period of 2024. Cash and cash equivalents As of March 31, 2025, the Company’s cash and cash equivalents amounted to RMB201.7 million (US$27.8 million), compared to RMB233.2 million as of December 31, 2024. Conference Call The Company’s management team will hold an earnings conference call at 8:00 A.M. Eastern Time on Friday, June 6, 2025 (8:00 P.M. Beijing/Hong Kong Time on Friday, June 6, 2025). Details for the conference call are as follows: Event Title: Huize Holding Limited’s First Quarter 2025 Earnings Conference CallRegistration Link: https://register-conf.media-server.com/register/BI0fd426b7ca0e4dd38aa44d82b96a9c7e All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registration, each participant will receive a confirmation email containing dial-in numbers and a unique access PIN, which will be used to join the conference call. Additionally, a live and archived webcast of the conference call will also be available on the Company’s investor relations website at http://ir.huize.com. About Huize Holding Limited Huize Holding Limited is a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data-driven and AI-powered solutions in Asia. Targeting mass affluent consumers, Huize is dedicated to serving consumers for their life-long insurance needs. Its online-to-offline integrated insurance ecosystem covers the entire insurance life cycle and offers consumers a wide spectrum of insurance products, one-stop services, and a streamlined transaction experience across all scenarios. By leveraging AI, data analytics, and digital capabilities, Huize empowers the insurance service chain with proprietary technology-enabled solutions for insurance consultation, user engagement, marketing, risk management, and claims service. For more information, please visit http://ir.huize.com or follow us on social media via LinkedIn (https://www.linkedin.com/company/huize-holding-limited), X(https://x.com/huizeholding) and Webull(https://www.webull.com/quote/nasdaq-huiz). Use of Non-GAAP Financial Measure Statement In evaluating our business, we consider and use non-GAAP net profit/(loss) attributable to common shareholders as a supplemental measure to review and assess our operating performance. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We define non-GAAP net profit/(loss) attributable to common shareholders as net profit/(loss) attributable to common shareholders excluding share-based compensation expenses. Such adjustments have no impact on income tax because either the non-GAAP adjustments were recorded at entities located in tax free jurisdictions, such as the Cayman Islands or because the non-GAAP adjustments were recorded at operating entities located in the PRC for which the non-GAAP adjustments were not deductible for tax purposes. We present the non-GAAP financial measure because it is used by our management to evaluate our operating performance and formulate business plans. Non-GAAP net profit/(loss) attributable to common shareholders enables our management to assess our operating results without considering the impact of share-based compensation expenses. We also believe that the use of this non-GAAP financial measure facilitates investors’ assessment of our operating performance. This non-GAAP financial measure is not defined under U.S. GAAP and is not presented in accordance with U.S. GAAP. The non-GAAP financial measure has limitations as an analytical tool. One of the key limitations of using adjusted net profit/(loss) attributable to common shareholders is that it does not reflect all items of income and expense that affect our operations. Further, the non-GAAP financial measure may differ from the non-GAAP financial information used by other companies, including peer companies, and therefore their comparability may be limited. The non-GAAP financial measure should not be considered in isolation or construed as an alternative to net profit/(loss) attributable to common shareholders or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review the historical non-GAAP financial measure in light of the most directly comparable GAAP measure, as shown below. The non-GAAP financial measure presented here may not be comparable to similarly titled measure presented by other companies. Other companies may calculate similarly titled measures differently, limiting the usefulness of such measures when analyzing our data comparatively. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure. Exchange Rate Information This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB7.2567 to US$1.00, the exchange rate on March 31, 2025, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollars amounts referred could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Huize’s beliefs and expectations, are forward-looking statements. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, business outlook and quotations from management in this announcement, contain forward-looking statements. Huize may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Huize’s goal and strategies; Huize’s expansion plans; Huize’s future business development, financial condition and results of operations; Huize’s expectation regarding the demand for, and market acceptance of, its online insurance products; Huize’s expectations regarding its relationship with insurer partners and insurance clients and other parties it collaborates with; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Huize’s filings with the SEC. All information provided in this press release is as of the date of this press release, and Huize does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For investor and media inquiries, please contact: Investor RelationsKenny LoInvestor Relations Managerinvestor@huize.com Media Relationsmediacenter@huize.com Christensen AdvisoryIn ChinaMs. Dee WangPhone: +86-10-5900-1548Email: dee.wang@christensencomms.com In U.S.Ms. Linda BergkampPhone: +1-480-614-3004Email: linda.bergkamp@christensencomms.com Huize Holding LimitedUnaudited Condensed Consolidated Balance Sheets(all amounts in thousands, except for share and per share data)   As of December 31,  As of March 31,  2024  2025  RMB RMB USDAssets      Current assets      Cash and cash equivalents 233,207  201,708  27,796 Restricted cash 61,708  54,525  7,514 Short-term investments 5,000  3,137  432 Contract assets, net of allowance for doubtful accounts 71,085  60,680  8,362 Accounts receivables, net of allowance for impairment 157,080  191,794  26,430 Insurance premium receivables 1,763  1,640  226 Amounts due from related parties 995  1,204  166 Prepaid expense and other receivables 68,171  68,225  9,402 Total current assets 599,009  582,913  80,328        Non-current assets      Restricted cash 29,883  29,883  4,118 Contract assets, net of allowance for expected credit losses 28,435  24,195  3,334 Property, plant and equipment, net 47,083  44,590  6,145 Intangible assets, net 68,840  69,785  9,617 Long-term investments 66,716  69,132  9,527 Operating lease right-of-use assets 20,715  17,126  2,360 Goodwill 14,536  14,536  2,003 Other assets 8,981  8,700  1,199 Total non-current assets 285,189  277,947  38,303 Total assets 884,198  860,860  118,631        Liabilities and Shareholders’ Equity      Current liabilities      Short-term borrowings 50,000  53,000  7,304 Accounts payable 202,054  202,697  27,932 Insurance premium payables 56,042  47,531  6,550 Other payables and accrued expenses 44,434  33,446  4,606 Payroll and welfare payable 41,005  41,776  5,757 Income taxes payable 2,575  2,575  355 Operating lease liabilities 16,743  14,901  2,053 Amount due to related parties 2,495  -  - Total current liabilities 415,348  395,926  54,557        Non-current liabilities      Long-term borrowings -  6,990  963 Deferred tax liabilities 14,875  14,848  2,046 Operating lease liabilities 24,082  19,806  2,729 Payroll and welfare payable 649  305  42 Accounts payable -  2,713  374 Total non-current liabilities 39,606  44,662  6,154 Total liabilities 454,954  440,588  60,711         Shareholders’ equity       Class A common shares 63  63  9 Class B common shares 10  10  1 Treasury stock (29,513) (29,513) (4,067)Additional paid-in capital 909,930  909,930  125,392 Accumulated other comprehensive loss (12,864) (12,311) (1,697)Accumulated deficits (458,886) (467,473) (64,414)Total shareholders’ equity attributable to Huize Holding Limited shareholders 408,740  400,706  55,224 Non-controlling interests 20,504  19,566  2,696 Total shareholders’ equity 429,244  420,272  57,920 Total liabilities and shareholders’ equity 884,198  860,860  118,631            Huize Holding LimitedUnaudited Condensed Consolidated Statements of Comprehensive Income/(Loss) (all amounts in thousands, except for share and per share data)   For the Three Months Ended March 31,  2024  2025  RMB RMB USDOperating revenue      Brokerage income 301,882  271,850  37,462 Other income 8,430  11,939  1,645 Total operating revenue 310,312  283,789  39,107 Operating costs and expenses      Cost of revenue (217,922) (209,012) (28,803)Other cost (2,273) (1,471) (203)Total operating costs (220,195) (210,483) (29,005)Selling expenses (44,205) (47,320) (6,521)General and administrative expenses (22,632) (21,905) (3,019)Research and development expenses (14,380) (13,471) (1,856)Total operating costs and expenses (301,412) (293,179) (40,402)Operating (loss)/profit  8,900  (9,390) (1,295)       Other income/(expenses)      Interest income 1,224  675  93 Unrealized exchange loss (293) (147) (19)Investment income/(loss) (2,325) 214  30 Others, net 1,950  736  101 (Loss)/profit before income tax, and share of loss of equity method investee 9,456  (7,912) (1,090)Income tax expense -  (152) (21)Share of loss of equity method investee (767) (1,460) (201)Net (loss)/profit 8,689  (9,524) (1,312)       Net (loss)/profit attributable to non-controlling interests 1,781  (937) (129)Net (loss)/profit attributable to Huize Holding Limited 6,908  (8,587) (1,183)       Net (loss)/profit 8,689  (9,524) (1,312)Foreign currency translation adjustment, net of tax 1,499  553  76 Comprehensive (loss)/profit 10,188  (8,971) (1,236)Comprehensive (loss)/income attributable to non-controlling interests 1,781  (937) (129)Comprehensive (loss)/income attributable to Huize Holding Limited  8,407  (8,034) (1,107)       Weighted average number of common shares used in computing net profit per share      Basic and diluted 988,410,632  1,008,857,623  1,008,857,623 Net (loss)/profit per share attributable to common shareholders      Basic and diluted 0.01  (0.01) (0.00)           Huize Holding LimitedUnaudited Reconciliations of GAAP and Non-GAAP Results(all amounts in thousands, except for share and per share data)   For the Three Months Ended March 31,  2024 2025  RMB RMB USDNet (loss)/profit attributable to common shareholders 6,908  (8,587) (1,183)Share-basedcompensation expenses (2,558) (2,354) (324)Non-GAAP net (loss)/profit attributable to common shareholders 4,350  (10,941) (1,508)           ______________________ 1 Non-GAAP net loss attributable to common shareholders is a non-GAAP financial measure. For more information, please see the section of “Use of Non-GAAP Financial Measure Statement” and the table captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results” set forth at the end of this press release.

Vesting and settlement of 2022 Conditional Share Awards and Notification of transactions by persons discharging managerial responsibilities - ForexTV

Vesting and settlement of 2022 Conditional Share Awards and Notification of transactions by persons discharging managerial responsibilities Serabi announces that on 5 June 2025 the Board of Directors approved the vesting of Conditional Share Awards that had been granted for the 2022 calendar year pursuant to the Company’s Long Term Incentive Plan (“LTIP”). In aggregate a total of 482,528 new ordinary shares (“the 2022 Awards”) were calculated as being due to vest to participants under the LTIP. The Board has assessed the level of performance compared with the targets for Total Shareholder Return, Return on Capital Employed and Return of Sales over the requisite three-year period. The terms of the Serabi 2020 Restricted Share Plan (the “2020 Plan”) under which the 2022 Awards were granted, require that awards are subject to a three-year performance period during which time certain performance criteria stipulated by the Board must be attained. In respect of the vesting of the 2022 Awards these were initially granted in respect of the calendar year 2022 and for which the measurement period was the 3 calendar years of 2022, 2023 and 2024 The performance criteria and minimum thresholds that were required to be achieved over the entirety of the three-year period were as follows: 40% of the award is subject to Total Shareholder Return, (where there will be 0% vesting if Serabi TSR is in line with the BMO junior gold index increasing in a linear manner up to 100% vesting under this KPI if Serabi hits 1.2x the index over same period.)30% of the award is subject to Return on Capital Employed (where ROCE premium over Weighted Average Cost of Capital (“WACC”) must be in excess of 1.05 times. If this hurdle is met vesting will occur in a linear manner such that 100% vesting of this portion is achieved at 1.2x WACC), and30% of the award is subject to Return on Sales (where ROS must exceed average annual budget by 10 per cent or more). The Board has, in light of the strong cash position of the Group and its desire to minimise the issuance of new ordinary shares, elected, in accordance with the rules of the 2020 Plan, to settle by way of a cash payment the value of the 2022 Awards that are due. The cash settlement has been determined by reference to the 20 Day VWAP price of the Ordinary Shares of the Company as at 5 June 2025 of £1.52, the date immediately prior to this announcement. In aggregate, 224,576 and 69,050 Conditional Share Awards which were otherwise due to vest to each of Mr Hodgson and Mr Howlin respectively will therefore be settled by a cash payment of £341,356 and £104,956 respectively from which the Company will make deduction of applicable taxes. The Board prioritises aligning the directors’ and shareholders’ interests and demonstrating their commitment to the business and Mike Hodgson has informed the Board that he has purchased 45,000 shares on 5 June 2026 through a market purchase at a price of £1.69. Mr Hodgson now beneficially holds 135,066 Ordinary Shares in the Company representing 0.18% of the issued shares in the Company. This announcement is made in accordance with the requirements of the UK Market Abuse Regulation. The notification of dealing forms can be found below. 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Michael Hodgson2 Reason for the notification a) Position/status PDMR - Chief Executive Officerb) Initial notification /Amendment Initial Notification3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Serabi Gold plcb) LEI 213800LTYC1HF9RTUE374 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Ordinary shares of one penny each  GB00BG5NDX91b) Nature of the transaction Purchase of sharesc) Price(s) and volume(s) Price(s) Volume(s)169.17 pence45,000 d) Aggregated information - Aggregated volume - Price N/a single transaction e) Date of the transaction 5 June 2025f) Place of the transaction   London Stock Exchange About Serabi Gold plcSerabi Gold plc is a gold exploration, development and production company focused on the prolific Tapajós region in Para State, northern Brazil. The Company has consistently produced 30,000 to 40,000 ounces per year with the Palito Complex and is planning to double production in the coming years with the construction of the Coringa Gold project. Serabi Gold plc recently made a copper-gold porphyry discovery on its extensive exploration licence. The Company is headquartered in the United Kingdom with a secondary office in Toronto, Ontario, Canada. The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. The person who arranged for the release of this announcement on behalf of the Company was Andrew Khov, Vice President, Investor Relations & Business Development. Enquiries SERABI GOLD plcMichael Hodgson        t +44 (0)20 7246 6830Chief Executive        m +44 (0)7799 473621 Andrew Khov        m +1 647 885 4874VP Investor Relations & Business Development         e contact@serabigold.com BEAUMONT CORNISH LimitedNominated Adviser & Financial AdviserRoland Cornish / Michael Cornish        t +44 (0)20 7628 3396 PEEL HUNT LLPJoint UK BrokerRoss Allister                t +44 (0)20 7418 9000 TAMESIS PARTNERS LLPJoint UK BrokerCharlie Bendon/ Richard Greenfield        t +44 (0)20 3882 2868 CAMARCOFinancial PR - EuropeGordon Poole / Emily Hall                t +44 (0)20 3757 4980 HARBOR ACCESSFinancial PR – North AmericaJonathan Paterson                t +1 475 477 9401 Copies of this announcement are available from the Company's website at www.serabigold.com. Forward-looking statementsCertain statements in this announcement are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ‘‘believe’’, ‘‘could’’, “should” ‘‘envisage’’, ‘‘estimate’’, ‘‘intend’’, ‘‘may’’, ‘‘plan’’, ‘‘will’’ or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements including risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets, reliance on key personnel, uninsured and underinsured losses and other factors, many of which are beyond the control of the Company. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Qualified Persons StatementThe scientific and technical information contained within this announcement has been reviewed and approved by Michael Hodgson, a Director of the Company. Mr Hodgson is an Economic Geologist by training with over 30 years' experience in the mining industry. He holds a BSc (Hons) Geology, University of London, a MSc Mining Geology, University of Leicester and is a Fellow of the Institute of Materials, Minerals and Mining and a Chartered Engineer of the Engineering Council of UK, recognizing him as both a Qualified Person for the purposes of Canadian National Instrument 43-101 and by the AIM Guidance Note on Mining and Oil & Gas Companies dated June 2009. NoticeBeaumont Cornish Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as nominated adviser to the Company in relation to the matters referred herein. Beaumont Cornish Limited is acting exclusively for the Company and for no one else in relation to the matters described in this announcement and is not advising any other person and accordingly will not be responsible to anyone other than the Company for providing the protections afforded to clients of Beaumont Cornish Limited, or for providing advice in relation to the contents of this announcement or any matter referred to in it. Neither the Toronto Stock Exchange, nor any other securities regulatory authority, has approved or disapproved of the contents of this news release. Attachment Vesting of LTIPs (cash settlement) v Final

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 - ForexTV

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025. “We are delighted that the results of the Phase 2 program were accepted for presentation at the ERA 2025 congress. This allowed Vivoryon to share the outstanding improvements of varoglutamstat on kidney function (eGFR) with the scientific and medical expert community in the kidney space,” said Frank Weber, MD, CEO of Vivoryon. Presentation HighlightsVaroglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with potent anti-inflammatory and anti-fibrotic effects. VIVIAD and VIVA-MIND, two independent Phase 2 studies in the EU and U.S. showed a statistically significant and clinically meaningful improvement in a prospectively defined kidney function parameter, eGFR, in an elderly patient population. This improvement was consistent in both trials independently, replicated in the meta-analysis and pooled analysis, and provides converging evidence for this finding. Statistically significant differences between varoglutamstat and placebo were first observed at week 24 and were sustained until week 96. The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes compared to those without diabetes. The next step is planned to be a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). The main goal will be to investigate the efficacy on eGFR in this patient population and to obtain additional information on a potential effect on proteinuria and other kidney specific markers. Presentation Details Date: June 6, 2025Presentation time: 8:15 am CEST as part of the focused oral sessionTitle: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studiesVenue: Vienna, Austria Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics ### About Vivoryon Therapeutics N.V.Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com Vivoryon Forward Looking Statements This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Investor ContactsVivoryon Therapeutics N.V.Dr. Manuela Bader, Director IR & CommunicationEmail: IR@vivoryon.com LifeSci AdvisorsSandya von der Weid Tel: +41 78 680 05 38Email: svonderweid@lifesciadvisors.com Media ContactTrophic CommunicationsValeria Fisher or Verena SchossmannTel: +49 175 8041816 / +49 151 219 412 77Email: vivoryon@trophic.eu Attachment 20250606_ERA_VVY

Burning Rock Reports First Quarter 2025 Financial Results - ForexTV

GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates Therapy Selection and MRD Personalized Minimal Residual Disease (MRD) product, CanCatch® Custom supports advancement in oesophageal squamous cell carcinoma（OSCC）treatment, with results published in the Molecular Cancer in May 2025. The study is a two-arm, multicenter, randomized, double-blind phase 2 study, comparing the efficacy of systemic treatment combining nCT with immunotherapy against nCT alone for OSCC patients. The study demonstrates that Perioperative Nivolumab plus chemotherapy is a viable and safe option for systemically treating locally advanced resectable OSCC, and monitoring minimal residual disease through ctDNA could be potentially valuable for assessing the effectiveness of adjuvant therapy and for prognostic evaluation in a systemic manner.Presented study results on non-small cell lung cancer and gastrointestinal stromal tumor (GIST) at the ASCO in June 2025. “Personalized tumor-informed ctDNA has the potential to inform recurrence in high-risk locally advanced stage GIST patients, especially for patients with irregular adjuvant therapy” and “MUSETALK-Lung01 (MUltiomics SEquencing Technique AppLication Kick-start) is a prospective, longitudinal, observational study designed to evaluate the clinical utility of a tumor-naïve ctDNA assay in patients with early-stage non-small cell lung cancer (NSCLC).”Presented multiple study results at the 2025 AACR in April, showcasing the clinical utility of the tumor-informed personalized MRD assay (CanCatch® Custom) and the tumor-naïve methylation-based MRD assay. First Quarter 2025 Financial Results Revenues were RMB133.1 million (US$18.3 million) for the three months ended March 31, 2025, representing a 5.9% increase from RMB125.6 million for the same period in 2024. Revenue generated from central laboratory business was RMB38.3 million (US$5.3 million) for the three months ended March 31, 2025, representing a 19.6% decrease from RMB47.6 million for the same period in 2024, primarily attributable to a decrease in the number of tests, as we continued to focus on our in-hospital business.Revenue generated from in-hospital business was RMB57.7 million (US$7.9 million) for the three months ended March 31, 2025, representing a 0.5% increase from RMB57.4 million for the same period in 2024, driven by a continuous growth in sales volume.Revenue generated from pharma research and development services was RMB37.1 million (US$5.1 million) for the three months ended March 31, 2025, representing a 79.9% increase from RMB20.6 million for the same period in 2024, primarily attributable to increased development and testing services performed for our pharma customers, and several milestones of our pharma programs were achieved. Cost of revenues was RMB35.7 million (US$4.9 million) for the three months ended March 31, 2025, representing a 10.6% decrease from RMB39.9 million for the same period in 2024, primarily due to a decrease in cost of central laboratory business, which was in line with the decrease in revenue generated from this business. Gross profit was RMB97.4 million (US$13.4 million) for the three months ended March 31, 2025, representing a 13.7% increase from RMB85.7 million for the same period in 2024. Gross margin was 73.2% for the three months ended March 31, 2025, compared to 68.2% for the same period in 2024. By channel, gross margin of central laboratory business was 84.1% for the three months ended March 31, 2025, compared to 77.7% during the same period in 2024, primarily due to a reduction in material and labor costs resulted from cost optimization and control measures and a decreased depreciation and rental cost in relation to our laboratory of Guangzhou headquarter; gross margin of in-hospital business was 76.1% for the three months ended March 31, 2025, compared to 68.3% during the same period in 2024, primarily due to the same reason; gross margin of pharma research and development services was 57.5% for the three months ended March 31, 2025, compared to 46.1% during the same period of 2024, primarily due to the cost optimization measures and an increase in test volume of higher margin projects. Non-GAAP gross profit, which excludes depreciation and amortization expenses, RMB100.7 million (US$13.9 million) for the three months ended March 31, 2025, representing an 8.3% increase from RMB93.0 million for the same period in 2024. Non-GAAP gross margin was 75.6% for the three months ended March 31, 2025, compared to 74.0% for the same period in 2024. Operating expenses were RMB112.6 million (US$15.5 million) for the three months ended March 31, 2025, representing a 46.8% decrease from RMB211.5 million for the same period in 2024. The decrease was primarily driven by budget control measures and headcount reduction to improve the Company’s operating efficiency. Research and development expenses were RMB40.4 million (US$5.6 million) for the three months ended March 31, 2025, representing a 38.8% decrease from RMB66.0 million for the same period in 2024, primarily due to (i) a decrease in amortized expense on share-based compensation; (ii) a decrease in the expenditure for detection research and (iii) a decrease in depreciation and amortization.Selling and marketing expenses were RMB40.9 million (US$5.6 million) for the three months ended March 31, 2025, representing a 12.7% decrease from RMB46.9 million for the same period in 2024, primarily due to (i) a decrease in staff cost resulted from the reorganization of our sales department to improve operating efficiency and (ii) a decrease in depreciation and amortization.General and administrative expenses were RMB31.3 million (US$4.3 million) for the three months ended March 31, 2025, representing a 68.3% decrease from RMB98.7 million for the same period in 2024, primarily due to (i) a decrease in amortized expense on share-based compensation; (ii) a decrease in depreciation and amortization; (iii) a decrease in staff cost resulted from the reorganization; and (iv) a decrease in operating lease expense for office building. Net loss was RMB13.5 million (US$1.9 million) for the three months ended March 31, 2025, compared to RMB121.5 million for the same period in 2024. Cash, cash equivalents and restricted cash were RMB497.4 million (US$68.5 million) as of March 31, 2025. Exchange Rate Information This press release contains translations of certain Renminbi amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars and from U.S. dollars to Renminbi are made at a rate of RMB7.2567 to US$1.00, the exchange rate on March 31, 2025, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollars amounts referred could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all. About Burning Rock Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. For more information about Burning Rock, please visit: ir.brbiotech.com. Safe Harbor Statement This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. Non-GAAP Measures In evaluating the business, the Company considers and uses non-GAAP measures, such as non-GAAP gross profit and non-GAAP gross margin, as supplemental measures to review and assess operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The company defines non-GAAP gross profit as gross profit excluding depreciation and amortization. The company defines non-GAAP gross margin as gross margin excluding depreciation and amortization. The company presents these non-GAAP financial measures because they are used by management to evaluate operating performance and formulate business plans. The company believe non-GAAP gross profit and non-GAAP gross margin excluding non-cash impact of depreciation and amortization reflect the company’s ongoing business operations in a manner that allows more meaningful period-to-period comparisons. Contact: IR@brbiotech.com Selected Operating Data  As of March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 March 31, 2025In-hospital Channel:         Pipeline partner hospitals(1)28 29 30 29 30Contracted partner hospitals(2)59 59 61 63 63Total number of partner hospitals87 88 91 92 93 (1)Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company’s products.(2)Refers to hospitals that have entered into contracts to purchase the Company’s products for use on a recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals.   Selected Financial Data  For the three months endedRevenuesMarch 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 March 31, 2025 (RMB in thousands)Central laboratory channel47,614 48,773 39,984 39,278 38,296In-hospital channel57,387 59,872 63,769 43,464 57,687Pharma research and development channel20,622 26,888 24,891 43,280 37,099Total revenues125,623 135,533 128,644 126,022 133,082            For the three months endedGross profitMarch 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025 (RMB in thousands)Central laboratory channel37,002 38,424 33,262 33,153 32,191In-hospital channel39,192 44,058 46,580 29,563 43,895Pharma research and development channel9,500 12,956 12,004 26,706 21,315Total gross profit85,694 95,438 91,846 89,422 97,401            For the three months endedShare-based compensation expensesMarch 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025 (RMB in thousands)Cost of revenues596 464 289 520 308Research and development expenses12,287 12,008 3,180 3,202 1,800Selling and marketing expenses508 1,232 1,917 1,353 1,025General and administrative expenses55,990 54,407 4,732 2,937 1,413Total share-based compensation expenses69,381 68,111 10,118 8,012 4,546           Burning Rock Biotech Limited Unaudited Condensed Statements of Comprehensive Loss (in thousands, except for number of shares and per share data)  For the three months ended March 31,2024 June 30,2024 September 30, 2024 December 31,2024 March 31, 2025 March 31, 2025 RMB RMB RMB RMB RMB US$Revenues125,623  135,533  128,644  126,022  133,082  18,340 Cost of revenues(39,929) (40,095) (36,798) (36,600) (35,681) (4,918)Gross profit85,694  95,438  91,846  89,422  97,401  13,422 Operating expenses:                 Research and development expenses(65,985) (64,952) (49,150) (52,203) (40,389) (5,566)Selling and marketing expenses(46,856) (48,907) (48,411) (46,730) (40,888) (5,635)General and administrative expenses(98,681) (92,794) (32,874) (37,289) (31,303) (4,314)Impairment loss on long-lived assets         (35,127)      Total operating expenses(211,522) (206,653) (130,435) (171,349) (112,580) (15,515)Loss from operations(125,828) (111,215) (38,589) (81,927) (15,179) (2,093)Interest income4,038  3,187  3,173  1,814  2,581  356 Other income (expense), net434  (82) 1  4,353  (652) (90)Foreign exchange (loss) gain, net(13) 262  (129) (220) (26) (4)Loss before income tax(121,369) (107,848) (35,544) (75,980) (13,276) (1,831)Income tax expenses(180) (190) (201) (5,314) (224) (31)Net loss(121,549) (108,038) (35,745) (81,294) (13,500) (1,862)Net loss attributable to Burning Rock Biotech Limited’s shareholders(121,549) (108,038) (35,745) (81,294) (13,500) (1,862)Net loss attributable to ordinary shareholders(121,549) (108,038) (35,745) (81,294) (13,500) (1,862)Loss per share for class A and class B ordinary shares:                 Class A ordinary shares - basic and diluted(1.19) (1.05) (0.35) (0.79) (0.13) (0.02)Class B ordinary shares - basic and diluted(1.19) (1.05) (0.35) (0.79) (0.13) (0.02)Weighted average shares outstanding used in loss per share computation:                 Class A ordinary shares - basic and diluted85,219,188  85,271,858  85,902,670  86,036,286  90,291,658  90,291,658 Class B ordinary shares - basic and diluted17,324,848  17,324,848  17,324,848  17,324,848  17,324,848  17,324,848 Other comprehensive income (loss), net of tax of nil:                 Foreign currency translation adjustments590  940  (4,054) 6,009  (72) (10)Total comprehensive loss(120,959) (107,098) (39,799) (75,285) (13,572) (1,872)Total comprehensive loss attributable to Burning Rock Biotech Limited’s shareholders(120,959) (107,098) (39,799) (75,285) (13,572) (1,872)                   Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets(In thousands)  As of December 31, 2024 March 31,2025 March 31,2025 RMB RMB US$ASSETS     Current assets:     Cash and cash equivalents519,849 495,145 68,233Restricted cash2,313 2,261 312Accounts receivable, net152,013 159,463 21,974Contract assets, net13,855 17,178 2,367Inventories, net62,625 65,424 9,016Prepayments and other current assets, net25,963 22,072 3,042Total current assets776,618 761,543 104,944Non-current assets:     Property and equipment, net47,152 41,162 5,672Operating right-of-use assets53,188 43,804 6,036Intangible assets, net421 386 53Other non-current assets7,926 7,822 1,078Total non-current assets108,687 93,174 12,839TOTAL ASSETS885,305 854,717 117,783       Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets (Continued)(in thousands)  As of December 31,2024 March 31,2025 March 31,2025 RMB RMB US$LIABILITIES AND SHAREHOLDERS’ EQUITY   Current liabilities:   Accounts payable33,747  35,938  4,952 Deferred revenue117,895  117,200  16,151 Accrued liabilities and other current liabilities89,498  76,198  10,501 Customer deposits592  592  82 Current portion of operating lease liabilities24,567  22,524  3,104 Total current liabilities266,299  252,452  34,790 Non-current liabilities:   Non-current portion of operating lease liabilities27,754  19,814  2,730 Other non-current liabilities10,425  10,649  1,467 Total non-current liabilities38,179  30,463  4,197 TOTAL LIABILITIES304,478  282,915  38,987     Shareholders’ equity:   Class A ordinary shares124  124  17 Class B ordinary shares21  21  3 Additional paid-in capital5,002,255  5,005,991  689,844 Treasury stock(63,264) (62,453) (8,606)Accumulated deficits(4,200,261) (4,213,761) (580,672)Accumulated other comprehensive loss(158,048) (158,120) (21,790)Total shareholders’ equity580,827  571,802  78,796 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY885,305  854,717  117,783           Burning Rock Biotech LimitedUnaudited Condensed Statements of Cash Flows(in thousands)  For the three months ended March 31,2024 March 31,2025 March 31,2025 RMB RMB US$Net cash generated from (used in) operating activities19,062  (23,527) (3,242)Net cash used in investing activities(812) (1,531) (211)Net cash used in financing activities(74) -  - Effect of exchange rate on cash, cash equivalents and restricted cash5,739  302  43 Net increase in (decrease) cash, cash equivalents and restricted cash23,915  (24,756) (3,410)Cash, cash equivalents and restricted cash at the beginning of period498,247  522,162  71,955 Cash, cash equivalents and restricted cash at the end of period522,162  497,406  68,545      Burning Rock Biotech LimitedReconciliations of GAAP and Non-GAAP Results   For the three months ended March 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025  (RMB in thousands)Gross profit:  Central laboratory channel37,002 38,424 33,262 33,153 32,191In-hospital channel39,192 44,058 46,580 29,563 43,895Pharma research and development channel9,500 12,956 12,004 26,706 21,315Total gross profit85,694 95,438 91,846 89,422 97,401Add: depreciation and amortization:     Central laboratory channel1,919 1,226 1,277 1,010 562In-hospital channel1,524 824 798 623 290Pharma research and development channel3,856 4,417 3,846 2,534 2,412Total depreciation and amortization included in cost of revenues7,299 6,467 5,921 4,167 3,264Non-GAAP gross profit：     Central laboratory channel38,921 39,650 34,539 34,163 32,753In-hospital channel40,716 44,882 47,378 30,186 44,185Pharma research and development channel13,356 17,373 15,850 29,240 23,727Total non-GAAP gross profit92,993 101,905 97,767 93,589 100,665Non-GAAP gross margin：     Central laboratory channel81.7% 81.3% 86.4% 87.0% 85.5%In-hospital channel70.9% 75.0% 74.3% 69.5% 76.6%Pharma research and development channel64.8% 64.6% 63.7% 67.6% 64.0%Total non-GAAP gross margin74.0% 75.2% 76.0% 74.3% 75.6%

QuantaSing Announces Unaudited Financial Results for the Third Quarter of Fiscal Year 2025 - ForexTV

BEIJING, June 06, 2025 (GLOBE NEWSWIRE) -- QuantaSing Group Limited (NASDAQ: QSG) (“QuantaSing” or the “Company”), a leading lifestyle solution provider, today announced its unaudited financial results for the third quarter of the fiscal year ending June 30, 2025 (the “third quarter of FY 2025”, which refers to the quarter from January 1, 2025 to March 31, 2025). Business and Financial Highlights for the Third Quarter of FY 2025 Revenues for the third quarter of FY 2025 were RMB570.7 million (US$78.6 million), representing a decrease of 21.5% from the second quarter of the fiscal year ending June 30, 2025 (the “second quarter of FY 2025”) and a decrease of 39.6% from the third quarter of the fiscal year ended June 30, 2024 (the “third quarter of FY 2024”).Gross billings of individual online learning services1 for the third quarter of FY 2025 were RMB515.6 million (US$71.0 million), representing a decrease of 5.6% from the second quarter of FY 2025 and a decrease of 47.5% from the third quarter of FY 2024.Net income for the third quarter of FY 2025 was RMB41.1 million (US$5.7 million), representing a decrease of 67.5% from the second quarter of FY 2025 and an increase of 181.2% from the third quarter of FY 2024.Adjusted net income2 for the third quarter of FY 2025 was RMB37.8 million (US$5.2 million), representing a decrease of 71.3% from the second quarter of FY 2025 and an increase of 18.5% from the third quarter of FY 2024.Total registered users increased by 19.9% to approximately 145.0 million as of March 31, 2025, from 121.0 million as of March 31, 2024.Paying learners was approximately 0.3 million in the third quarter of FY 2025. Company Highlight for the Third Quarter of FY 2025 Completed acquisition of 61% equity interest in Shenzhen Yiqi Culture Co., Ltd. ("Letsvan") on March 31, 2025 for a total cash consideration of RMB235.0 million through a multi-step transaction. Results of operations of Letsvan were included in consolidated financials of the Company beginning April 1, 2025. The acquired assets and liabilities of Letsvan are included at fair value in the Company’s consolidated balance sheet as of March 31, 2025. Mr. Peng Li, Chairman and Chief Executive Officer of QuantaSing, commented, “Our third quarter results reflect our strategic pivot toward product-driven business models that create long-term value. The acquisition of Letsvan marks a significant milestone in our expansion into the pop toys market, a sector with strong growth potential that perfectly aligns with our brand-first philosophy. The early success of our WAKUKU IP, including the recent Fox and Rabbit collection launch, validates our approach of pairing strong product development capabilities with efficient go-to-market strategies. As we integrate Letsvan's operations, we're applying our test-and-scale methodology to build a global presence in this resilient market segment. We aim to create businesses where brand strength and product excellence drive sustainable growth, rather than simply pursuing traffic-driven metrics.” Mr. Dong Xie, Chief Financial Officer of QuantaSing, added, “Our financial performance this quarter underscores our commitment to disciplined capital allocation during this transformation phase. While revenue moderated to RMB570.7 million as we shifted resources away from traffic-driven businesses, we've maintained strong cash generation across our businesses. Our ROI-focused assessment methodology has allowed us to exit underperforming areas while preserving resources for high-potential opportunities. With our healthy cash position, we have the flexibility to support both our existing operations and our strategic initiatives in the pop toys space. Though we anticipate some near-term profitability fluctuations as we optimize our business mix, our financial foundation remains robust as we execute this strategic evolution.” Financial Results for the Third Quarter of FY 2025 Revenues Revenues were RMB570.7 million (US$78.6 million) in the third quarter of FY 2025, compared to RMB945.6 million in the third quarter of FY 2024. The change reflects the Company's deliberate shift from traffic-driven growth to high-quality growth. Revenues from individual online learning services decreased by 43.6% year over year to RMB467.2 million (US$64.4 million) in the third quarter of FY 2025, from RMB828.1 million in the third quarter of FY 2024. This decrease was primarily due to a decrease of RMB268.3 million (US$37.0 million) in revenues from skills upgrading courses, a decline of RMB74.1 million (US$10.2 million) in revenues from financial literacy courses and a decline of RMB18.5 million (US$2.5 million) in revenues from recreation and leisure courses.Revenues from enterprise services were RMB48.1 million (US$6.6 million) in the third quarter of FY 2025, compared to RMB65.1 million in the third quarter of FY 2024, representing a year-over-year change of 26.1%. The decline was primarily driven by reduced marketing services to enterprise customers.Revenues from consumer business3 were RMB48.7 million (US$6.7 million) in the third quarter of FY 2025, compared to RMB49.4 million in the third quarter of FY 2024. The slight change was primarily attributable to the decline in baijiu revenue, partially offset by the modest increase in wellness products revenue.Revenues from others3 were RMB6.7 million (US$0.9 million) in the third quarter of FY 2025, compared to RMB3.0 million in the third quarter of FY 2024, primarily due to revenue from the Company’s newly initiated business. Cost of revenues Cost of revenues was RMB96.6 million (US$13.3 million) in the third quarter of FY 2025, compared to RMB145.8 million in the third quarter of FY 2024, representing a 33.8% decrease. The decrease was primarily due to reduced labor outsourcing costs of RMB22.1 million (US$3.1 million), decreased procurement costs of RMB9.6 million (US$1.3 million) and lower staff costs of RMB5.1 million (US$0.7 million). Sales and marketing expenses Sales and marketing expenses were RMB395.2 million (US$54.5 million) in the third quarter of FY 2025, compared to RMB729.6 million in the third quarter of FY 2024, representing a decrease of 45.8%. The decrease was mainly due to a reduction in marketing and promotion expenses of RMB265.1 million (US$36.5 million), labor outsourcing costs of RMB46.4 million (US$6.4 million), and staff costs of RMB7.9 million (US$1.1 million), which included a decrease in share-based compensation expenses of RMB2.1 million (US$0.3 million). Research and development expenses Research and development expenses were RMB20.9 million (US$2.9 million) in the third quarter of FY 2025, compared to RMB38.8 million in the third quarter of FY 2024, representing a decrease of 46.2%. The decrease was primarily due to lower staff costs of RMB16.0 million (US$2.2 million). General and administrative expenses General and administrative expenses were RMB25.0 million (US$3.5 million) in the third quarter of FY 2025, compared to RMB36.4 million in the third quarter of FY 2024, representing a decrease of 31.2%. The decrease was primarily due to lower staff costs of RMB8.0 million (US$1.1 million), which included a decrease in share-based compensation expenses of RMB5.5 million (US$0.8 million). Remeasurement gain of previously held equity interests in connection with step acquisitions Remeasurement gain of previously held equity interests in connection with step acquisitions were RMB8.1 million (US$1.1 million) in the third quarter of FY 2025, reflecting the fair value adjustment of initial investments in Letsvan before obtaining control. Details of the acquisition can be found in the Recent Developments section of this report. Others, net Others, net were RMB15.4 million (US$2.1 million) in the third quarter of FY 2025, compared to RMB7.7 million in the third quarter of FY 2024, primarily driven by the increased fair value gains in one of the Company’s long-term investments. Net income and adjusted net income Net income was RMB41.1 million (US$5.7 million) in the third quarter of FY 2025, compared to RMB14.6 million in the third quarter of FY 2024. Adjusted net income was RMB37.8 million (US$5.2 million) in the third quarter of FY 2025, compared to RMB31.9 million in the third quarter of FY 2024. Earnings per share and adjusted earnings per share4 Basic and diluted net income per share were both RMB0.25 (US$0.03) in the third quarter of FY 2025, compared to basic and diluted net income per share of RMB0.09 in the third quarter of FY 2024. Basic and diluted adjusted net income per share were RMB0.23 (US$0.03), in the third quarter of FY 2025, compared to RMB0.19 in the third quarter of FY 2024. Balance Sheet As of March 31, 2025, the Company had cash and cash equivalents, restricted cash and short-term investments of RMB1,134.9 million (US$156.4 million), compared with RMB1,026.3 million as of June 30, 2024. Recent Developments Investments in Letsvan On March 24, 2025, the Company announced that it entered into definitive agreements to invest in Shenzhen Yiqi Culture Co., Ltd., a PRC-based company specializing in IP incubation, copyright commercialization, and the promotion and sales of pop toys. The transaction marks the Company's strategic entry into the pop toys market and broader consumer goods sector. Upon the completion of the investments in March 2025, Letsvan became a controlled subsidiary of the Company. Letsvan currently operates a number of established IPs, including "WAKUKU", "ZIYULI", "FUNII", "FIILA" and "PIDOL", with distribution channels spanning both online and offline platforms across China and Southeast Asian markets. Letsvan’s current growth strategy encompasses three key areas: strengthening collaborations with major retail partners to enhance IP influence and expand sales, developing self-operated retail locations including a recently opened pop-up store at Chaoyang Joy City in Beijing, and building comprehensive online brand and sales capabilities. International expansion initiatives are underway. Letsvan has already established its footprints in certain Southeast Asian markets and has been exploring opportunities in other overseas markets including the United States. With respect to IPs, Letsvan continues to strengthen internal product incubation and operational capabilities, partner with third-party artists, and collaborate with established IPs to diversify its product portfolio. Recent product launches include the "WAKUKU Fox and Bunny Trick or Treat", which commenced offline distribution on May 17, 2025, followed by online channel availability on May 20, 2025. The Beijing Chaoyang Joy City pop-up store launch has generated favorable user response and increased product visibility in the market. 2024 Share Repurchase Program On June 11, 2024, the Company announced that the Board had approved a share repurchase program of up to US$20.0 million of the Company’s Class A ordinary shares in the form of ADSs for a 12-month period beginning on June 11, 2024 and ending on June 10, 2025 (the “2024 Share Repurchase Program”). As of March 31, 2025, a total of 1.7 million ADSs had been repurchased for an aggregate consideration of US$3.6 million under the 2024 Share Repurchase Program. 2025 Share Repurchase Program On June 6, 2025, the Company announced that the Board had approved a new share repurchase program of up to US$20.0 million of the Company’s Class A ordinary shares in the form of ADSs for a purchase period beginning from June 11, 2025 and ending on June 30, 2026 (the “2025 Share Repurchase Program”). Repurchases under the 2025 Share Repurchase Program may be made from time to time through open market transactions at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means. The repurchases will be subject to all applicable rules and regulations, including Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, as well as the Company’s insider trading policy. The number of ADSs repurchased and the timing of repurchases will also depend on a number of factors, including, but not limited to, price, trading volume and general market conditions, along with the Company’s working capital requirements, general business conditions and other factors. The Board will review the 2025 Share Repurchase Program periodically, and may authorize adjustment of its terms and size or suspend or discontinue the program. The Company plans to fund the repurchases from its existing cash balance. Conference Call Information The Company's management team will hold an earnings conference call at 07:00 A.M. Eastern Time on Friday, June 6, 2025 (07:00 P.M. Beijing Time on the same day) to discuss the financial results. Listeners may access the call by dialing the following numbers: International: 1-412-902-4272United States Toll Free: 1-888-346-8982Mainland China Toll Free: 4001-201203Hong Kong Toll Free: 800-905945Conference ID: QuantaSing Group Limited    The replay will be accessible through June 13, 2025 by dialing the following numbers: International: 1-412-317-0088United States Toll Free: 1-877-344-7529Replay Access Code: 3611954    A live and archived webcast of the conference call will be available at the Company's investor relations website at https://ir.quantasing.com. Non-GAAP Financial Measures To supplement the Company’s consolidated financial statements, which are prepared and presented in accordance with U.S. GAAP, the Company uses gross billings of individual online learning services, adjusted net income and basic and diluted adjusted net income per share as its non-GAAP financial measures. Gross billings of individual online learning services for a specific period represents revenues of the Company’s individual online learning services net of the changes in deferred revenues in such period, further adjusted by value-added tax in such period. Adjusted net income represents net income excluding share-based compensation expenses and remeasurement gain of previously held equity interests inconnection with step acquisitions. Basic and diluted adjusted net income per share represents adjusted net income attributable to QuantaSing Group Limited divided by weighted average number of ordinary shares outstanding during the periods used in computing adjusted net income per share, basic and diluted. The Company believes that the non-GAAP financial measures provide useful information about the Company's results of operations, enhance the overall understanding of the Company's past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company's management in its financial and operational decision-making. The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools, and when assessing the Company's operating performance, investors should not consider them in isolation, or as a substitute for revenue, net income, net income per share, basic and diluted or other consolidated statements of operations data prepared in accordance with U.S. GAAP. The Company's definition of non-GAAP financial measures may differ from those of industry peers and may not be comparable with their non-GAAP financial measures. The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company's performance. For more information on these non-GAAP financial measures, please see the table captioned “QuantaSing Group Limited Unaudited Reconciliation of GAAP and Non-GAAP Results” near the end of this release. Exchange Rate Information This announcement contains translations of certain Renminbi (“RMB”) amounts into U.S. dollars (“US$”) at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from Renminbi to U.S. dollars were made at the rate of RMB7.2567 to US$1.00, the exchange rate on March 31, 2025, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollars amounts referred to could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all. Safe Harbor Statements This announcement contains forward-looking statements within the meaning of Section 27A of Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended and the Private Securities Litigation Reform Act of 1955. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding QuantaSing’s financial outlook, beliefs and expectations. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” “guidance” and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s growth strategies; its future business development, results of operations and financial condition; its ability to attract and retain new users and learners and to increase the spending and revenues generated from users and learners; its ability to maintain and enhance the recognition and reputation of its brand; its expectations regarding demand for and market acceptance of its services and products; the expected growth, trends and competition in the markets that the Company operates in; changes in its revenues and certain cost or expense items; PRC governmental policies and regulations relating to the Company’s business and industry, general economic and political conditions in China and globally, and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties, or factors is included in the Company’s filings with the SEC, including, without limitation, the final prospectus related to the IPO filed with the SEC dated January 24, 2023. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. About QuantaSing Group Limited QuantaSing is a leading lifestyle solution provider that offers engaging, affordable and accessible online and offline services, as well as consumer products in selected areas that address senior users' wellness aspirations. QuantaSing has expanded into the pop toys sector and continues to strategically diversify its portfolio by capturing opportunities in promising consumer sectors while maintaining financial discipline. For more information, please visit: https://ir.quantasing.com. Contact Investor RelationsLeah GuoQuantaSing Group LimitedEmail: ir@quantasing.comTel: +86 (10) 6493-7857 Robin Yang, PartnerICR, LLCEmail: QuantaSing.IR@icrinc.comPhone: +1 (212) 537-0429 _________________________________1 Gross billings of individual online learning services is a non-GAAP financial measure. For a reconciliation of revenues of individual online learning services to gross billings of individual online learning services, see the “Non-GAAP Financial Measures” section and the table captioned “QuantaSing Group Limited Unaudited Reconciliation of GAAP and Non-GAAP Results” below.2 Adjusted net income is a non-GAAP financial measure. For a reconciliation of net income to adjusted net income, see the “Non-GAAP Financial Measures” section and the table captioned “QuantaSing Group Limited Unaudited Reconciliation of GAAP and Non-GAAP Results” below.3 Effective from the fourth quarter of FY 2024, the Company has introduced “Revenues from Consumer Business” as a separate line item. This revenue was previously included in “Revenues from Others”. The historical revenues presentation has been conformed to the current presentation.4 Basic and diluted adjusted net income per share are non-GAAP financial measures. For a reconciliation of basic and diluted net income per share to basic and diluted adjusted net income per share, see the “Non-GAAP Financial Measures” section and the table captioned “QuantaSing Group Limited Unaudited Reconciliation of GAAP and Non-GAAP Results” below. QUANTASING GROUP LIMITEDUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in thousands, except for share and per share data)  As of June 30,2024 March 31,2025 March 31,2025 RMB RMB US$      ASSETS     Current assets:     Cash and cash equivalents779,931 985,677 135,830Restricted cash160 675 93Short-term investments246,195 148,532 20,468Accounts receivable, net16,676 37,392 5,153Amounts due from related parties4,488 489 67Inventory, net6,345 28,120 3,875Prepayments and other current assets275,549 173,582 23,920Total current assets1,329,344 1,374,467 189,406      Non-current assets:     Property and equipment, net6,569 11,571 1,595Long-term investments9,010 44,428 6,122Intangible assets, net- 68,973 9,505Operating lease right-of-use assets58,889 29,479 4,062Deferred tax assets847 914 126Goodwill- 187,598 25,852Other non-current assets21,360 5,177 713Total non-current assets96,675 348,140 47,975TOTAL ASSETS1,426,019 1,722,607 237,381      LIABILITIES     Current liabilities:     Short-term Borrowings- 14,500 1,998Accounts payables62,066 55,219 7,609Accrued expenses and other current liabilities190,508 186,084 25,643Income tax payable20,399 53,565 7,381Contract liabilities, current portion385,227 310,189 42,745Advance from customers162,257 148,332 20,441Operating lease liabilities, current portion49,099 30,837 4,249Total current liabilities869,556 798,726 110,066      Non-current liabilities:     Contract liabilities, non-current portion11,365 33,495 4,616Operating lease liabilities, non-current portion16,989 3,123 430Deferred tax liabilities11,625 42,269 5,825Total non-current liabilities39,979 78,887 10,871TOTAL LIABILITIES909,535 877,613 120,937       QUANTASING GROUP LIMITEDUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS- continued(Amounts in thousands, except for share and per share data)  As of June 30,2024 March 31,2025 March 31,2025 RMB RMB US$      MEZZANINE EQUITY     Non-controlling interests with liquidation preferences-  40,999  5,650       SHAREHOLDERS’ EQUITY     Class A ordinary shares81  81  11 Class B ordinary shares34  34  5 Treasury stock(109,257) (41,898) (5,774)Additional paid-in capital1,192,474  1,069,620  147,398 Accumulated other comprehensive income17,313  18,491  2,548 Accumulative deficit(584,161) (335,573) (46,243)TOTAL QUANTASING GROUP LIMITED SHAREHOLDERS’ EQUITY516,484  710,755  97,945 Non-controlling interests-  93,240  12,849 TOTAL SHAREHOLDERS’ EQUITY516,484  803,995  110,794 TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY1,426,019  1,722,607  237,381           QUANTASING GROUP LIMITEDUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME(Amounts in thousands, except for shares and per share data)     For the Three MonthsEnded March 31, For the Nine MonthsEnded March 31, 2024  2025  2025  2024  2025  2025  RMB  RMB  US$  RMB  RMB  US$             Revenues945,570  570,706  78,645  2,795,248  2,107,757  290,457 Cost of revenues(145,848) (96,556) (13,306) (409,058) (353,516) (48,716)            Gross Profit799,722  474,150  65,339  2,386,190  1,754,241  241,741             Operating expenses:           Sales and marketing expenses(729,620) (395,175) (54,457) (2,006,884) (1,317,206) (181,516)Research and development expenses(38,840) (20,891) (2,879) (123,655) (77,325) (10,656)General and administrative expenses(36,390) (25,049) (3,452) (114,211) (86,194) (11,878)Total operating expenses(804,850) (441,115) (60,788) (2,244,750) (1,480,725) (204,050)            (Loss)/Income from operations(5,128) 33,035  4,551  141,440  273,516  37,691             Other income:           Interest income2,513  880  121  8,369  4,040  557 Remeasurement gain of previously held equity interests in connection with step acquisitions-  8,109  1,117  -  8,109  1,117 Others, net7,685  15,400  2,122  22,163  31,418  4,330             Income before income tax5,070  57,424  7,911  171,972  317,083  43,695 Income tax benefit/(expense)9,560  (16,280) (2,243) 16,948  (68,495) (9,439)            Net income14,630  41,144  5,668  188,920  248,588  34,256 Net loss attributable to noncontrolling interests-  1  -  -  1  - Net income attributable to QuantaSing Group Limited14,630  41,145  5,668  188,920  248,589  34,256             Other comprehensive income/(loss)           Foreign currency translation adjustments, net of nil tax423  (289) (40) (4,954) 1,178  162 Total other comprehensive income/(loss)423  (289) (40) (4,954) 1,178  162             Total comprehensive income15,053  40,855  5,628  183,966  249,766  34,418 Total comprehensive loss attributable to noncontrolling interests-  1  -  -  1  - Comprehensive income attributable to QuantaSing Group Limited15,053  40,856  5,628  183,966  249,767  34,418             Net income per ordinary share           - Basic0.09  0.25  0.03  1.14  1.55  0.21 - Diluted0.09  0.25  0.03  1.10  1.52  0.21 Weighted average number of ordinary shares used in computing net income per share           - Basic164,753,256  162,791,862  162,791,862  166,399,349  160,479,027  160,479,027 - Diluted170,890,581  165,216,173  165,216,173  171,089,530  163,949,787  163,949,787 Share-based compensation expenses included in           Cost of revenues(2,878) (1,431) (197) (9,945) (5,214) (719)Sales and marketing expenses(2,779) (642) (88) 8,678  (1,540) (212)Research and development expenses(3,599) (167) (23) (10,611) (2,474) (341)General and administrative expenses(8,039) (2,571) (354) (28,961) (8,073) (1,112)                   QUANTASING GROUP LIMITEDUNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS(Amounts in thousands, except for shares and per share data) The following table below sets forth a reconciliation of revenues to gross billings for the periods indicated:  For the Three MonthsEnded March 31, For the Nine MonthsEnded March 31, 2024  2025  2025  2024  2025  2025  RMB  RMB  US$  RMB  RMB  US$             Revenues of individual online learning services:828,127  467,247  64,388  2,457,588  1,777,552  244,953 Add: value-added tax52,986  27,919  3,847  147,665  101,969  14,052 Add: ending deferred revenues(1)744,320  461,026  63,531  744,320  461,026  63,531 Less: beginning deferred revenues(1)(643,929) (440,632) (60,721) (661,360) (565,030) (77,863)​           Gross billings of individual online learning services981,504  515,560  71,045  2,688,213  1,775,517  244,673  (1) Deferred revenues include contract liabilities, advance from customers, and refund liability of individual online learning services included in “accrued expenses and other current liabilities”.  QUANTASING GROUP LIMITEDUNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS - continued(Amounts in thousands, except for shares and per share data) The following table below sets forth a reconciliation of net income to adjusted net income and basic and diluted net income per share to basic and diluted adjusted net income per share for the periods indicated:  For the Three MonthsEnded March 31, For Nine MonthsEnded March 31, 2024 2025  2025  2024 2025  2025  RMB RMB  US$  RMB RMB   US$             Net income14,630 41,144  5,668  188,920 248,588  34,256 Add: Share-based compensation expenses17,295 4,811  662  40,839 17,301  2,384 Less: Remeasurement gain of previously held equity interests in connection with step acquisitions- (8,109) (1,117) - (8,109) (1,117)​           Adjusted net income31,925 37,846  5,213  229,759 257,780  35,523 Attributable to noncontrolling interests- 1  -  - 1  - Adjusted net income attributable to QuantaSing Group Limited31,925 37,847  5,213  229,759 257,781  35,523             Weighted average number of ordinary shares used in computing net income per share           - Basic164,753,256 162,791,862  162,791,862  166,399,349 160,479,027 160,479,027 - Diluted170,890,581 165,216,173  165,216,173  171,089,530 163,949,787 163,949,787 Weighted average number of ordinary shares used in computing adjusted net income per share           - Basic164,753,256 162,791,862  162,791,862  166,399,349 160,479,027 160,479,027 - Diluted170,890,581 165,216,173  165,216,173  171,089,530 163,949,787 163,949,787             Net income per ordinary share           - Basic0.09 0.25  0.03  1.14 1.55 0.21 - Diluted0.09 0.25  0.03  1.10 1.52 0.21 Non-GAAP adjustments to net income per ordinary share           - Basic0.10 (0.02) 0.00  0.24 0.06 0.01 - Diluted0.10 (0.02) 0.00  0.24 0.05 0.01 Adjusted net income per ordinary share           - Basic0.19 0.23  0.03  1.38 1.61 0.22 - Diluted0.19 0.23  0.03  1.34 1.57 0.22

Top Wall Street Forecasters Revamp G-III Apparel Expectations Ahead Of Q1 Earnings - G-III Apparel Group (NASDAQ:GIII) - Benzinga